PANAXIA LABS ISRAEL LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,578 ILa | +24.76% |
|
+18.01% | -36.10% |
| Mar. 31 | Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 10 | Joseph Herman acquired 3.33% stake in Panaxia Labs Israel Ltd for ILS 1 million. | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 46.83 | 284.4 | 138.2 | 28.3 | 22.44 |
| Enterprise Value (EV) 1 | 46.23 | 283.8 | 161.1 | 64.41 | 58.55 |
| P/E ratio | -2.85 x | -8.37 x | -6.21 x | -0.65 x | -168 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 2.81 x | 4.68 x | 1.65 x | 0.72 x | 1.15 x |
| EV / Revenue | 2.77 x | 4.67 x | 1.93 x | 1.63 x | 2.99 x |
| EV / EBITDA | -1.63 x | -8.26 x | -4.77 x | -1.77 x | -6.77 x |
| EV / FCF | -4,164,745 x | -11,245,824 x | -4,558,960 x | -45,897,886 x | 47,282,155 x |
| FCF Yield | -0% | -0% | -0% | -0% | 0% |
| Price to Book | 30.3 x | 10.5 x | 7.17 x | -1.28 x | -126 x |
| Nbr of stocks (in thousands) | 17.7 | 107 | 147 | 150 | 150 |
| Reference price 2 | 2,643 | 2,646 | 943.0 | 189.0 | 149.9 |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/21/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.101 | 16.69 | 60.75 | 83.6 | 39.42 | 19.59 |
| EBITDA 1 | -6.71 | -28.43 | -34.35 | -33.77 | -36.33 | -8.654 |
| EBIT 1 | -7.058 | -29 | -35.35 | -34.91 | -37.77 | -10.61 |
| Operating Margin | -172.1% | -173.77% | -58.19% | -41.76% | -95.82% | -54.18% |
| Earnings before Tax (EBT) 1 | -6.928 | -81.37 | -35.9 | -21.38 | -43.6 | -13.4 |
| Net income 1 | -6.923 | -81.34 | -35.9 | -21.38 | -43.27 | -13.4 |
| Net margin | -168.81% | -487.38% | -59.1% | -25.57% | -109.77% | -68.43% |
| EPS 2 | -84.15 | -926.7 | -316.3 | -151.8 | -289.0 | -0.8900 |
| Free Cash Flow | - | -11.1 | -25.24 | -35.34 | -1.403 | 1.238 |
| FCF margin | - | -66.51% | -41.55% | -42.27% | -3.56% | 6.32% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/30/20 | 3/31/21 | 3/31/22 | 3/21/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 8.49 | - | - | 22.9 | 36.1 | 36.1 |
| Net Cash position 1 | - | 0.6 | 0.57 | - | - | - |
| Leverage (Debt/EBITDA) | -1.265 x | - | - | -0.6791 x | -0.994 x | -4.172 x |
| Free Cash Flow | - | -11.1 | -25.2 | -35.3 | -1.4 | 1.24 |
| ROE (net income / shareholders' equity) | - | -8,058% | -184% | -85.8% | 3,519% | 46.4% |
| ROA (Net income/ Total Assets) | - | -89% | -40.2% | -26.4% | -36.8% | -29.5% |
| Assets 1 | - | 91.35 | 89.32 | 81.08 | 117.7 | 45.44 |
| Book Value Per Share 2 | -41.90 | 87.40 | 253.0 | 131.0 | -148.0 | -1.190 |
| Cash Flow per Share 2 | 2.700 | 143.0 | 139.0 | 19.70 | 18.70 | 0.0100 |
| Capex 1 | 0.51 | 3.35 | 4.93 | 1.65 | 0.37 | - |
| Capex / Sales | 12.51% | 20.04% | 8.11% | 1.97% | 0.94% | - |
| Announcement Date | 3/30/20 | 3/30/20 | 3/31/21 | 3/31/22 | 3/21/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -36.10% | 3.76M | |
| +10.55% | 67.6B | |
| +11.64% | 18.21B | |
| +20.68% | 13.41B | |
| +9.40% | 13.37B | |
| +17.24% | 9.94B | |
| -32.37% | 5.74B | |
| -10.98% | 5.57B | |
| -4.09% | 4.91B | |
| -4.83% | 4.87B |
- Stock Market
- Equities
- PNAX Stock
- Financials Panaxia Labs Israel Ltd
